<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <link rel="stylesheet" href="./css/commonCss.css">
    <link rel="stylesheet" href="./css/aboutCss.css">
    <script src="./javaScript/jquery3.5.js"></script>
</head>
<body>
    <div id="navbar">
        <li><a href="index.html"><img src="./images/covid19_2.png" alt=""></a></li>
        <li><a href="testing.html">Testing</a></li>
        <li><a href="about.html">About</a></li>
        <li><a href="precautions.html">Precautions</a></li>
        <li>
            <div id="menu-btn">
                <div class="menu-bar"></div>
                <div class="menu-bar"></div>
            </div>
        </li>
    </div>

    <div id="navbar-drop">
        <li><a href="testing.html">Testing</a></li>
        <li><a href="about.html">About</a></li>
        <li><a href="precautions.html">Precautions</a></li>
    </div>

    <div id="container">
        <div class="head">About</div>
        <p>
            Driven by the philanthropic philosophy of affordable vaccines;Serum Institute of India Pvt, Ltd. (SIIPL)is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses), supplying the world's cheapest and WHO accredited vaccines to as many as 170 countries. It was founded in 1966 with the aim of manufacturing lifesaving immunobiological drugs including vaccines worldwide.
        </p>
        <p>
            Serum Institute of India to produce covid-19 vaccine doses for India and low and middle income countries in 2021.
        </p>
        <p>
            The announcement takesforward the collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of a further US$150 million to Gavi, bringing the total funding provided through this collaboration to US$300 million.The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.
        </p>
        <p>
            The funding will help accelerate the manufacturing by SII for candidate vaccines licensed from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification. The vaccines will have a ceiling price of US$3 per dose, a price enabled by investments made by partners such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill and Melinda Gates Foundation and SII.
        </p>
        <p>
            Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation –over 760 million children –and prevented more than 13 million deaths, helping to halve child mortality in 73 developing countries.
        </p>
    </div>

    <div class="footer">
        Created by Rahit Mondal
    </div>

    <script src="./javaScript/myJs.js"></script>
</body>
</html>